Jump to content

New drug Rubraca approved by the FDA for metastatic castrate resistant men who have damage to their BRCA1/2 genes


Recommended Posts

Jim Marshall (not a doctor) said ...

In the USA the FDA (Food and Drug Administration) has approved the use of a new drug, Rubraca® (rucaparib), for the treatment of prostate cancer for men with:

  • Metastases (cancer moved away from the prostate);
  • Damaged BRCA1 or BRCA2 genes (genes that repair damage to DNA);

In the TRITON2 clinical trial, 44% of these men had a measurable response. About half of these had a response of more than six months, the longest being twenty-four months.

Rubraca worked whether you inherited the BRCA damage from your family (germline) or whether you developed the damage yourself in your prostate cancer (somatic).

Approval of Rubraca is the first step. Insurance companies (in the USA) and the PBAC (in Australia) will have to decide whether to cover the cost (which, of course, depends on the price).

Rubracca is one of a family of drugs called PARP inhibitors.

... end Jim



The article is not on this site.

If you click on the link, you will be taken to a site where we do not control the content.

So, please be careful about what you read there, and ask your doctor about anything you read.

You may need to subscribe to the site to view the article.

If the site is temporarily or permanently unavailable, you may receive an error message.

Link to comment
Share on other sites

Thanks for the info Jim,

I may need it at some time. I guess its a bit like Olaparib, in a family of PARP inhibitors. 

But rucaparib only gives 2 years if a man is real lucky. 

Regards to all,

Patrick Turner.  

Link to comment
Share on other sites

  • Create New...